Shopping Cart
- Remove All
Your shopping cart is currently empty
Drinabant (AVE-1625) is an orally active CB1 receptor antagonist. Drinabant inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $73 | In Stock | |
| 5 mg | $160 | In Stock | |
| 10 mg | $247 | In Stock | |
| 25 mg | $409 | In Stock | |
| 50 mg | $596 | In Stock | |
| 100 mg | $848 | In Stock | |
| 200 mg | $1,130 | In Stock |
| Description | Drinabant (AVE-1625) is an orally active CB1 receptor antagonist. Drinabant inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R. |
| Targets&IC50 | CB1 receptor (rat):10 nM, CB2:10000 nM, CB1 receptor (human):25 nM |
| In vivo | Drinabant (10 mg/kg orally once daily), combined with Olanzapine attenuates body weight gain, diminishing the enhanced food intake while maintaining increased energy expenditure and decreased motility[2]. Drinabant (1, 3, and 10 mg/kg ip), reverses abnormally persistent LI induced by MK-801 or neonatal nitric oxide synthase inhibition in rodents, and improves both working and episodic memory[3]. |
| Synonyms | AVE-1625, AVE1625 |
| Molecular Weight | 497.38 |
| Formula | C23H20Cl2F2N2O2S |
| Cas No. | 358970-97-5 |
| Smiles | C(N1CC(N(S(C)(=O)=O)C2=CC(F)=CC(F)=C2)C1)(C3=CC=C(Cl)C=C3)C4=CC=C(Cl)C=C4 |
| Relative Density. | 1.458 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (100.53 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.02 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.